leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences recieves US patent for Covid-19 treatment

Tiziana Life Sciences PLC's (LON:TILS, NASDAQ:TLSA) Dr Kunwar Shailubhai tells Proactive London about its latest US patent for its TZLS-501 antibody. The treatment is being developed to help people with life-threatening effects of the coronavirus (COVID-19). This comes at a time when Tiziana has been awarded several patents for multiple projects with four key patents being issued in the last few weeks and three of these patents were issued on the same day.

Quick facts: Tiziana Life Sciences PLC

Price: 139 GBX

AIM:TILS
Market: AIM
Market Cap: £265.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

4 hours, 37 minutes ago

2 min read